Nothing Special   »   [go: up one dir, main page]

MX2022008392A - Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. - Google Patents

Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.

Info

Publication number
MX2022008392A
MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A
Authority
MX
Mexico
Prior art keywords
methyl
phenylcyclohexyl
piperidine
oxy
carboxylate
Prior art date
Application number
MX2022008392A
Other languages
English (en)
Inventor
Hong Lu
Helene Faessel
Mark Rogge
Karthik Venkatakrishnan
Liming Zhang
John Wagner
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022008392A publication Critical patent/MX2022008392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen composiciones que comprenden (a) 3-((metilsulfonil)amino)-2-(((4-fenilciclohexil)oxi )metil)piperidina-1-carboxilato de metilo o una sal del mismo; y (b) un agente para reducir el metabolismo de (a) y usos del mismo.
MX2022008392A 2020-01-10 2021-01-07 Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. MX2022008392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959514P 2020-01-10 2020-01-10
PCT/US2021/012447 WO2021142083A1 (en) 2020-01-10 2021-01-07 A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450

Publications (1)

Publication Number Publication Date
MX2022008392A true MX2022008392A (es) 2022-08-08

Family

ID=74418549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008392A MX2022008392A (es) 2020-01-10 2021-01-07 Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.

Country Status (10)

Country Link
US (1) US20230029486A1 (es)
EP (1) EP4087534A1 (es)
JP (1) JP2023510332A (es)
KR (1) KR20220127245A (es)
CN (1) CN115226390A (es)
AU (1) AU2021205892A1 (es)
BR (1) BR112022013547A2 (es)
CA (1) CA3167050A1 (es)
MX (1) MX2022008392A (es)
WO (1) WO2021142083A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155885A1 (en) 2019-11-25 2021-06-03 Lewis D. Pennington Substituted macrocyclic compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902613A1 (en) * 2013-03-14 2014-10-02 Pharmacyclics Llc Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
PT3984994T (pt) 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Ltd Composto de piperidina substituída como agonista de orexina tipo 2 para o tratamento da narcolepsia

Also Published As

Publication number Publication date
CN115226390A (zh) 2022-10-21
CA3167050A1 (en) 2021-07-15
EP4087534A1 (en) 2022-11-16
AU2021205892A1 (en) 2022-08-18
WO2021142083A1 (en) 2021-07-15
JP2023510332A (ja) 2023-03-13
KR20220127245A (ko) 2022-09-19
US20230029486A1 (en) 2023-02-02
BR112022013547A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022008392A (es) Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
MX2021012645A (es) Metodos y composiciones para editar acidos ribonucleicos (arn).
WO2008027932A3 (en) Cytochrome p450 oxidase inhibitors and uses thereof
TN2009000249A1 (en) Mapk/erk kinase inhibitors
ATE498620T1 (de) 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs
WO2008014332A3 (en) Methods and apparatuses for directing an ion beam source
BRPI0519608A2 (pt) composiÇço de revestimento, mÉtodo para proteger uma superfÍcie de substrato,e, artigo
TW200834248A (en) Liquid-immersion exposure method and liquid-immersion exposure apparatus
TW200507831A (en) Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl]2-methylpropanethioate and an HMG CoA reductase inhibitor
MX2022003018A (es) Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
BR0115196A (pt) Métodos e composições para o controle de coccidiose
WO2022079128A3 (en) Compositions and methods for masking off-notes in consumables
TW200610036A (en) Improved magnet for scanning ion beams
CO2019001046A2 (es) Mancha blanca
HRP20050557A2 (en) Method for improving the pharmacokinetics of a nnrti
WO2004066027A3 (en) Electron beam processing for mask repair
EP4227380A4 (en) COMPOSITION CONTAINING A REFRIGERANT, AND METHOD FOR STABILIZING A COMPOSITION CONTAINING A REFRIGERANT
EP3872841A4 (en) DRY ETCHING GAS COMPOSITION WITH A SULFUR CONTAINING FLUOROCARBON COMPOUND WITH UNSATURATED BOND AND DRY ETCHING PROCESS THEREOF
WO2023049790A3 (en) Mdm2 degraders and uses thereof
AU2003237241A1 (en) Composition, kit and method for cleaning and/or treating surfaces
NO20063826L (no) Sammensetninger omfattende HIV-proteaseinhibitor og cytokrom P450 enzymaktivitetsinhibitor
SI1904490T1 (sl) Etanolaminska sol N-(3-metoksi-5-metilpirazin-2-il)-2-(4-(1,3,4-oksadiazol-2-il)fenil)- piridin-3-sulfonamida
TW200802593A (en) Etching method